After making its debut on Canada's NEO Exchange, MindMed made its Nasdaq debut. The mental health wellness company uses psychedelic substances as treatments for patients.
Psychedelics have made tremendous mainstream progress when it comes to the general public understanding the benefits, but Rahn said it's just "early innings for the entire industry and for our company" after becoming the first publicly traded psychedelics treatment company a year ago.
"For many, many years, solutions in the mental health space just really haven't been moving the needle in solving mental health for folks, and so what MindMed is doing is reimagining and reengineering how we are approaching mental health," CEO J.R. Rahn told Cheddar. "But we're doing it through substances like LSD, MDMA, psilocybin, these are psychedelics that from the 1960s were really demonized by society but we see great promise in what we call psychedelic-assisted therapy."
However, while marijuana legalization efforts have been going the route of deregulating for both medical and recreational purposes, Rahn said he doesn't believe the psychedelic industry should take the same path, touting the company's plan on sticking to FDA approval.
"I think the cannabis industry is vastly different than what we're trying to achieve here in the psychedelics medicine industry. There was a lot of mistakes made in cannabis. It's still not federally legal in the United States," he explained. "Our objective is to make these medicines accessible in all 50 states and all at the same time and do that in a scalable manner because 40 percent of the country needs these medicines. I think we are, as a company, going to stay away from legalization efforts and really just focus on the FDA pathway because that is how medicines ultimately get approved in the United States."
However, while he emphasized MindMed's approach through the U.S. government's regulatory framework, Rahn recognized that efforts to legalize and decriminalize psychedelics as the "voice of the people" hoping to find new solutions for mental health conditions.
MindMed trading under the ticker symbol MNMD closed at $4.02 per share on the day.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Scott Trench, host of the BiggerPockets Money Podcast, explores how recent rate cuts, high borrowing costs, and mortgage rates are reshaping U.S. real estate.
A look into how disruption, AI, and global economic trends are transforming the modern supply chain with Jeremy Jansen, Head of Supply Chain at Wells Fargo.
